Adult Dosing
Cystic fibrosis; respiratory infection prevention
- 300 mg NEB q12 hrs for 28 days, off for 28 days, then repeat cycle
- Powder for inhalation: 4 capsules (28 mg/capsule) inhaled q12 hrs for 28 days, off for 28 days, then repeat cycle
Note:- Tobi capsules are only for oral inhalation and should only be used with the Podhaler device
Pediatric Dosing
- Safety and effectiveness in children <6 yrs of age have not been established
Cystic fibrosis
- Child (>6 yrs): 300 mg NEB q12 hrs for 28 days, off for 28 days, then repeat cycle
- Child (>6 yrs): Powder for inhalation: 4 capsules (28 mg/capsule) inhaled q12 hrs for 28 days, off for 28 days, then repeat cycle
Note:- Tobi capsules are only for oral inhalation and should only be used with the Podhaler device
[Outline]
See Supplemental Patient Information
- Safety and effectiveness not established in patients <6 yrs of age, FEV1 <25% or >75% predicted or colonization w/ burkholderia cepacia
- Monitor patients receiving concomitant parenteral aminoglycosides for signs of renal toxicity, neurotoxicity, and ototoxicity
- Parenteral therapy is associated with ototoxicity, manifested as both auditory and vestibular toxicity. Vestibular toxicity may be manifested by vertigo, ataxia or dizziness
- Transient tinnitus and hearing loss may occur in patients receiving inhaled tobramycin
- Aminoglycosides may aggravate muscle weakness in patients with neuromuscular disorders due to a potential curare-like effect at the neuromuscular junction. Use drug with caution in patients with neuromuscular disorders, hypomagnesemia, hypocalcemia, or hypokalemia
- Bronchospasm can occur with inhalation route
- Monitor BUN/creatinine and serum drug levels (if renally impaired) or concomitant parenteral therapy
- Monitor audiometry for high risk patients or if symptoms of hearing impairment occur
Cautions: Use cautiously in
- Renal impairment
- Impaired auditory function
- Impaired vestibular function
- Concurrent ototoxic agents
- Concurrent neurotoxic agents
- Electrolyte abnormalities
- Dehydration
- Neuromuscular dysfunction
- Pulmonary impairment
- Electrolyte imbalances
- Myasthenia gravis
- Parkinson's disease
- Long term use
Supplemental Patient Information
- A Patient Medication Guide is provided with the container
Pregnancy Category:D
Breastfeeding: Safety unknown; due to potential for ototoxicity and nephrotoxicity in infants, breastfeeding is not recommended.
Pricing data from www.DrugStore.com in U.S.A.
- Tobi 300 MG/5ML NEBU [Plas Cont] (NOVARTIS)
5 5ml = $97.99
15 5ml = $282.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
